BACKGROUND: The use of granulocyte colony-stimulating factor (G-CSF) as a prophylaxis against febrile neutropenia (FN) is well documented in the literature; however, the therapeutic use of G-CSF in the treatment of FN remains controversial. This study assessed the efficacy of adjunctive G-CSF in the treatment of FN by evaluating clinical outcomes. METHODS: This was a single-center, prospective cohort study conducted at the National Cancer Center in Singapore. Adult patients who had received chemotherapy and developed FN between January 2009 and January 2012 were included in the analysis. The clinical efficacy of adjunctive G-CSF was evaluated by investigating the duration of hospitalization, duration to absolute neutrophil count (ANC) recovery, duration of grade IV neutropenia, duration to fever resolution, duration of antibiotic therapy, and incidence of documented infections. A multivariate analysis was performed to identify patients who could potentially benefit from adjunctive G-CSF. RESULTS: Four hundred and thirty patients were analyzed. Majority manifested low-risk FN (81.2%) based on the Multinational Association of Supportive Care in Cancer (MASCC) scoring. Compared to patients who did not receive adjunctive G-CSF, patients receiving adjunctive G-CSF had a nonsignificant reduction in the duration of hospitalization (3.5 vs. 3.7 days, p = 0.41) and in ANC recovery time (3.4 vs. 3.5 days, p = 0.76). Neutropenia-related mortality was lower among those who have received adjunctive G-CSF (2.4 vs. 8.4%, p = 0.006). Patients of Indian ethnicity and those who underwent gemcitabine-containing chemotherapy were less likely to receive adjunctive G-CSF treatment. CONCLUSIONS: This observational study suggested that adjunctive G-CSF may confer clinical benefits among solid tumor and lymphoma patients with established febrile neutropenia. Further research should be conducted to validate the findings.
BACKGROUND: The use of granulocyte colony-stimulating factor (G-CSF) as a prophylaxis against febrile neutropenia (FN) is well documented in the literature; however, the therapeutic use of G-CSF in the treatment of FN remains controversial. This study assessed the efficacy of adjunctive G-CSF in the treatment of FN by evaluating clinical outcomes. METHODS: This was a single-center, prospective cohort study conducted at the National Cancer Center in Singapore. Adult patients who had received chemotherapy and developed FN between January 2009 and January 2012 were included in the analysis. The clinical efficacy of adjunctive G-CSF was evaluated by investigating the duration of hospitalization, duration to absolute neutrophil count (ANC) recovery, duration of grade IV neutropenia, duration to fever resolution, duration of antibiotic therapy, and incidence of documented infections. A multivariate analysis was performed to identify patients who could potentially benefit from adjunctive G-CSF. RESULTS: Four hundred and thirty patients were analyzed. Majority manifested low-risk FN (81.2%) based on the Multinational Association of Supportive Care in Cancer (MASCC) scoring. Compared to patients who did not receive adjunctive G-CSF, patients receiving adjunctive G-CSF had a nonsignificant reduction in the duration of hospitalization (3.5 vs. 3.7 days, p = 0.41) and in ANC recovery time (3.4 vs. 3.5 days, p = 0.76). Neutropenia-related mortality was lower among those who have received adjunctive G-CSF (2.4 vs. 8.4%, p = 0.006). Patients of Indian ethnicity and those who underwent gemcitabine-containing chemotherapy were less likely to receive adjunctive G-CSF treatment. CONCLUSIONS: This observational study suggested that adjunctive G-CSF may confer clinical benefits among solid tumor and lymphomapatients with established febrile neutropenia. Further research should be conducted to validate the findings.
Authors: Otavio A C Clark; Gary H Lyman; Aldemar A Castro; Luciana G O Clark; Benjamin Djulbegovic Journal: J Clin Oncol Date: 2005-06-20 Impact factor: 44.544
Authors: S Y Hor; S C Lee; C I Wong; Y W Lim; R C Lim; L Z Wang; L Fan; J Y Guo; H S Lee; B C Goh; T Tan Journal: Pharmacogenomics J Date: 2007-09-18 Impact factor: 3.550
Authors: T Berghmans; M Paesmans; J J Lafitte; C Mascaux; A P Meert; C Jacquy; A Burniat; E Steels; F Vallot; J P Sculier Journal: Support Care Cancer Date: 2001-11-23 Impact factor: 3.603
Authors: F A Holmes; J A O'Shaughnessy; S Vukelja; S E Jones; J Shogan; M Savin; J Glaspy; M Moore; L Meza; I Wiznitzer; T A Neumann; L R Hill; B C Liang Journal: J Clin Oncol Date: 2002-02-01 Impact factor: 44.544
Authors: Alison G Freifeld; Eric J Bow; Kent A Sepkowitz; Michael J Boeckh; James I Ito; Craig A Mullen; Issam I Raad; Kenneth V Rolston; Jo-Anne H Young; John R Wingard Journal: Clin Infect Dis Date: 2011-02-15 Impact factor: 9.079
Authors: M A López-Hernández; R Jiménez-Alvarado; R Borbolla-Escoboza; J de Diego Flores-Chapa; M Alvarado-Ibarra; M González-Avante; M E Trueba-Chrysti; I Anaya-Cuéllar Journal: Gac Med Mex Date: 2000 Mar-Apr Impact factor: 0.302
Authors: P Riikonen; U M Saarinen; A Mäkipernaa; L Hovi; A Komulainen; J Pihkala; H Jalanko Journal: Pediatr Infect Dis J Date: 1994-03 Impact factor: 2.129
Authors: E J Anaissie; S Vartivarian; G P Bodey; C Legrand; H Kantarjian; D Abi-Said; C Karl; S Vadhan-Raj Journal: Am J Med Date: 1996-01 Impact factor: 4.965